Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Large Drop in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 41,438 shares, a drop of 36.3% from the February 12th total of 65,013 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 632,342 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 632,342 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Sysmex Trading Down 4.2%

Shares of Sysmex stock opened at $8.71 on Friday. The business has a fifty day simple moving average of $9.44 and a 200-day simple moving average of $10.58. Sysmex has a fifty-two week low of $8.15 and a fifty-two week high of $19.85. The firm has a market cap of $5.48 billion, a price-to-earnings ratio of 18.15 and a beta of 1.14. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. Sysmex had a return on equity of 9.27% and a net margin of 8.86%.The company had revenue of $837.32 million during the quarter, compared to the consensus estimate of $819.99 million. On average, equities analysts forecast that Sysmex will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.